

Austin, Texas

The Indigent Care Collaboration (ICC) has been working on a Pharmacy Initiative over the past year that is aimed at reducing the costs of pharmaceuticals through a three pronged-strategy: 1) Maximizing individual member participation in the federal 340B program, 2) Forming a purchasing group to negotiate discounts with pharmaceutical companies on behalf of both 340B and non-340B eligible members, and 3) Submitting an Alternative Methods Demonstration application to the federal Office of Pharmacy Affairs (OPA) to allow for the formation of a network of 340B entities and to expand the definition of patients served by the network. Through the development and use of an ICC-wide Preferred Drug List (PDL) and with the volume of purchases from this PDL, the ICC seeks to achieve sub-ceiling prices for its 340B eligible members, and near-340B prices for its non-340B members (Note: 340B prices average 49% of AWP. An additional 7-8% cost reduction for 340B entities can be achieved through the use of a PDL and group purchasing. These additional cost reductions are called sub-ceiling prices).